MRNA vs REGN
Moderna and Regeneron Pharmaceuticals, both Healthcare
Regeneron Pharmaceuticals is the larger company at $84B against $82B. Over the past year MRNA returned +658% against +42% for REGN.
| Figure | MRNA | REGN |
|---|---|---|
| Last close | $207 | $816 |
| Market cap | $82B | $84B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 20.2 |
| 1-year return | +658% | +42% |
| 5-year return | -36% | +50% |
| RyuScoresector-relative, 1–10 | n/a | 66/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit (Losses), 50% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.